Company Interview / A 'defining moment' in the world's largest healthcare market

Paul Anderson of Orthocell (ASX: OCC) shares the exciting news that their nerve repair device, Remplir, has received FDA clearance in the US. This milestone opens access to a $1.67 billion market, pivotal for Orthocell's future growth in the largest healthcare market worldwide.

Remplir is a unique product aiding surgeons in nerve repair without harmful sutures, leading to better healing and consistent outcomes. Paul notes the high demand for the product among US surgeons, emphasising the groundwork done over two years to establish logistics and key collaborations.

Despite market challenges, Orthocell shares experience a modest 3% drop, which Paul considers strong given the circumstances. With $32 million in the bank, Orthocell is well-capitalised to expand globally, particularly in the US, Singapore, and New Zealand, while absorbing tariffs thanks to healthy margins.